Evidence map›Paper›PMID 40450122›Full record

ReviewHead and neck pathology2025

Erdheim-Chester Disease of the Jaws: A Case Report and Review of the Literature.

Joud Y Omari, Marc L Nevins, Gideon P Smith, Reshma S Menon, Sook-Bin Woo

Abstract readCase ReportsReview
In one paragraph

Review in Head and neck pathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Joud Y OmariDepartment of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA. Joud_omari@hsdm.harvard.edu.ORCID http://orcid.org/0009-0007-9049-4292
Marc L NevinsDepartment of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA.
Gideon P SmithDepartment of Dermatology, Massachusetts General Hospital, Boston, MA, USA.
Reshma S MenonDepartment of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA.
Sook-Bin WooDepartment of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytic disease characterized by xanthogranulomatous infiltration of multiple organ systems by histiocytes that are negative for langerin (CD207) and CD1a. BRAF V600E mutation is present in 54% of the cases. The disease most commonly affects males in their 5th and 7th decades and bone is involved in 96% of cases although there have been only 8 reported cases of ECD involving the jaws. This is a case of ECD in a 57-year-old male who presented for extractions and implant placement. Radiographic examination revealed extensive bone loss in the posterior mandible and maxilla. Biopsy of the lytic lesions showed infiltration by epithelioid histiocytes with Touton-type multinucleated giant cells that were positive for BRAF and CD163 and negative for CD1a, consistent with the patient’s known history of ECD. He had been diagnosed with ECD 8 years prior with involvement of the long bones and subsequently the skin. The patient started vemurafenib treatment in July 2020 for progressive disease and his disease remains stable. Of the 8 previously reported cases involving the jaws, the median age at diagnosis was 35 years and both genders were equally affected. Reports describe multiple, often bilateral, mixed lytic-sclerotic lesions. Both the mandible and maxilla were affected in 75% of the cases and the mandible alone was involved in one case. None of the cases affected the maxilla alone. Current management includes the use of BRAF inhibitors and MEK inhibitors in the presence of BRAF mutations.

Indexed as

Erdheim-Chester DiseaseJaw DiseasesHumansMaleMiddle AgedVemurafenibVemurafenibBRAF V600E mutationErdheim-Chester diseaseHistiocytosisVemurafenib

Identifiers

PMID40450122
PMCPMC12126395

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.